Thrombocytopenia at baseline is a predictor of inhospital mortality in patients undergoing percutaneous coronary intervention

American Heart Journal

Volumn 156, Issue 1, 2008, Pages 120-124

  Overgaard, Christopher B ^a   Ivanov, Joan ^a   Seidelin, Peter H ^a   Todorov, Mina ^a   Mackie, Karen ^a   Džavík, Vladimír ^a  

^a UNIVERSITY HEALTH NETWORK   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ACUTE KIDNEY FAILURE; ADULT; ANGIOGRAPHY; ARTICLE; BRAIN HEMORRHAGE; CANADA; CLINICAL STUDY; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; FALSE ANEURYSM; FEMALE; GASTROINTESTINAL HEMORRHAGE; GROIN HEMATOMA; HEALTH; HEART INFARCTION; HEMATOMA; HUMAN; INFORMATION PROCESSING; INSTITUTIONAL CARE; INTRAOCULAR HEMORRHAGE; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; MORTALITY; MULTIVARIATE ANALYSIS; OUTCOME ASSESSMENT; PERCUTANEOUS CORONARY INTERVENTION; PREDICTION; PREDICTOR VARIABLE; PRIORITY JOURNAL; PROSPECTIVE STUDY; RETROPERITONEAL HEMORRHAGE; RISK; STATISTICAL SIGNIFICANCE; THROMBOCYTE; THROMBOCYTE COUNT; THROMBOCYTOPENIA; UNIVERSITY;

AGED; ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; CASE-CONTROL STUDIES; CONFIDENCE INTERVALS; CORONARY ANGIOGRAPHY; CORONARY DISEASE; FEMALE; FOLLOW-UP STUDIES; HOSPITAL MORTALITY; HUMANS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; ODDS RATIO; POSTOPERATIVE COMPLICATIONS; PREDICTIVE VALUE OF TESTS; PROBABILITY; RETROSPECTIVE STUDIES; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX; SURVIVAL ANALYSIS; THROMBOCYTOPENIA; TREATMENT OUTCOME;

EID: 45649083232     PISSN: 00028703     EISSN: 10976744     Source Type: Journal    
DOI: 10.1016/j.ahj.2008.02.003     Document Type: Article

References (18)

1. Lewis B. Thrombocytopenia and outcome in invasive cardiology. J Invasive Cardiol 14 Suppl B (2002) 38B-47B
2. Manor S.M., Guillory G.S., and Jain S.P. Clopidogrel-induced thrombotic thrombocytopenic purpura-hemolytic uremic syndrome after coronary artery stenting. Pharmacotherapy 24 (2004) 664-667
3. Nikolsky E., Sadeghi H.M., Effron M.B., et al. Impact of in-hospital acquired thrombocytopenia in patients undergoing primary angioplasty for acute myocardial infarction. Am J Cardiol 96 (2005) 474-481
4. Berkowitz S.D., Sane D.C., Sigmon K.N., et al. Occurrence and clinical significance of thrombocytopenia in a population undergoing high-risk percutaneous coronary revascularization. Evaluation of c7E3 for the Prevention of Ischemic Complications (EPIC) Study Group. J Am Coll Cardiol 32 (1998) 311-319
5. Merlini P.A., Rossi M., Menozzi A., et al. Thrombocytopenia caused by abciximab or tirofiban and its association with clinical outcome in patients undergoing coronary stenting. Circulation 109 (2004) 2203-2206
6. Salengro E., Mulvihill N.T., and Farah B. Acute profound thrombocytopenia after use of eptifibatide for coronary stenting. Catheter Cardiovasc Interv 58 (2003) 73-75
7. Kereiakes D.J., Berkowitz S.D., Lincoff A.M., et al. Clinical correlates and course of thrombocytopenia during percutaneous coronary intervention in the era of abciximab platelet glycoprotein IIb/IIIa blockade. Am Heart J 140 (2000) 74-80
8. Makoni S.N. Acute profound thrombocytopenia following angioplasty: the dilemma in the management and a review of the literature. Heart 86 (2001) E18
9. McClure M.W., Berkowitz S.D., Sparapani R., et al. Clinical significance of thrombocytopenia during a non-ST-elevation acute coronary syndrome. The platelet glycoprotein IIb/IIIa in unstable angina: receptor suppression using integrilin therapy (PURSUIT) trial experience. Circulation 99 (1999) 2892-2900
10. Nagge J., Jackevicius C., Dzavik V., et al. Acute profound thrombocytopenia associated with eptifibatide therapy. Pharmacotherapy 23 (2003) 374-379
11. Sideris S.K., Bonios M.J., Eftihiadis E.E., et al. Severe thrombocytopenia after heparin therapy in a patient with unstable angina and recent stent implantation. Hellenic J Cardiol 46 (2005) 242-246
12. Bovill E.G., Terrin M.L., Stump D.C., et al. Hemorrhagic events during therapy with recombinant tissue-type plasminogen activator, heparin, and aspirin for acute myocardial infarction. Results of the Thrombolysis in Myocardial Infarction (TIMI), Phase II Trial. Ann Intern Med 115 (1991) 256-265
13. Harrington R.A., Sane D.C., Califf R.M., et al. Clinical importance of thrombocytopenia occurring in the hospital phase after administration of thrombolytic therapy for acute myocardial infarction. The Thrombolysis and Angioplasty in Myocardial Infarction Study Group. J Am Coll Cardiol 23 (1994) 891-898
14. Best P.J., Mathew V., and Markovic S.N. Clopidogrel-associated autoimmune thrombocytopenic purpura. Catheter Cardiovasc Interv 62 (2004) 339-340
15. Smith Jr. S.C., Dove J.T., Jacobs A.K., et al. ACC/AHA guidelines of percutaneous coronary interventions (revision of the 1993 PTCA guideline)-executive summary. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (committee to revise the 1993 guidelines for percutaneous transluminal coronary angioplasty). J Am Coll Cardiol 37 (2001) 2215-2239
16. Hanley J.A., and McNeil B.J. The meaning and use of the area under a receiver operating characteristic (ROC) curve. Radiology 143 (1982) 29-36
17. Hosmer D., and Lemeshow S. Applied Logistic Regression (1989), John Wiley & Sons, New York
18. Vanderschueren S., De Weerdt A., Malbrain M., et al. Thrombocytopenia and prognosis in intensive care. Crit Care Med 28 (2000) 1871-1876